Kindred Biosciences, Inc. develops therapeutics for pet-specific treatments.
- We initiated our position in the 4th quarter of 2014, when Kindred announced plans to discontinue its AtoKin study, which caused a major decline in the stock price.
- Kindred announced positive results for its horse fever drug, Zimeta, in conjunction with unfavorable results for its Sentikind product in the 4th quarter of 2015. Stock declined due to the failed SentiKind drug, allowing us to add to our position over several months following the news.
- In the first quarter of 2016, Kindred announced positive results in for Mirataz, which helps the management of weight in cats. Believing the upside from Mirataz and Zimeta were not represented in the stock, we added to our position.
- Anticipation for FDA approval for Zimeta and Mirataz, coupled with improved long-term outlook, has contributed to recent appreciation in stock price.
Headquartered just outside of San Francisco and founded in 2012, Kindred Biosciences (KIN) is a biopharmaceutical company focused on developing drug candidates for pets. The company’s unique business model leverages compounds and targets that have been previously identified as effective on humans in order to develop therapeutics for pet-specific treatments. By utilizing previously identified compounds, Kindred Biosciences is able to shorten its development timeline, while controlling costs. Currently, the company is working on developing drugs for over 20 potential indications.
Deep Value Checklist
In our deep value portfolios, we believe asset protection and balance sheet strength are two key components of an attractive investment opportunity. With over 60% of its market capitalization in net cash and no debt on its balance sheet, Kindred Biosciences meets these characteristics. A strong management team with sizable inside ownership adds to our conviction, as co-founder Dr. Richard Chin currently serves as Chief Executive Officer (CEO) and owns over 13% of outstanding shares. Dr. Chin has previous experience in various roles at Genentech, and as CEO of OneWorld Health and Oxigene.
Over the past few years, two failed product candidates have weighed heavily on the stock, providing an opportunity to initiate, and subsequently add to, our position. However, recent developments indicate the potential for two marketready drug candidates. Kindred Biosciences completed pivotal trials for Zimeta and Mirataz, reporting positive and statistically significant topline results for both trials. Zimeta treats fever in horses, while Mirataz helps manage weight loss in cats. Management expects to launch both product candidates in 2017.
Attractive Risk/Reward Profile
In our view, the company is at a critical inflection point. The potential launch of Zimeta and Mirataz remain underappreciated by investors, despite a recent rally in the stock price (+55.6% YTD as of 9/30/16). In fact, we believe the current market opportunity for these two product candidates more than justifies the company’s current market capitalization. The remaining extensive product pipeline provides further upside opportunity. With a strong balance sheet, our investment thesis ultimately rests on our perceived downside protection, coupled with upside opportunities. Overall, Kindred Biosciences is well positioned within the pet pharmaceutical industry to take advantage of an underserved market.
Investing in small/micro-cap stocks is more risky and more volatile than investing in large cap stocks. The intrinsic value of the stocks in which Ariel Discovery Fund invests may never be recognized by the broader market. Our perception of downside protection cannot protect investors from the volatility associated with stocks, incorrect assumptions or estimations on our part, declining fundamentals or external forces. On this page, we candidly discuss a selected individual company to illustrate our investment process. The information and our opinions were current as of December 31, 2016, but are subject to change. The information shown does not provide information reasonably sufficient upon which to base an investment decision and should not be considered a recommendation to purchase or sell any particular security. Past performance does not guarantee future results. The performance of any single portfolio holding is no indication of the performance of other portfolio holdings of Ariel Discovery Fund or of Ariel Discovery Fund itself. Click here for performance data for Ariel Discovery Fund. Portfolio holdings are subject to change. These holdings do not represent all of Ariel Discovery Fund’s holdings. Click here for a full listing of Ariel Discovery Fund’s portfolio holdings.
Investors should consider carefully the investment objectives, risks, and charges and expenses before investing. For a current summary prospectus or full prospectus which contains this and other information about the funds offered by Ariel Investment Trust, call us at 800-292-7435 or click here. Please read the summary prospectus or full prospectus carefully before investing. Distributed by Ariel Distributors, LLC, a wholly-owned subsidiary of Ariel Investments, LLC.